Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment

Hirofumi Taki; Yukio Kawagishi; Koichiro Shinoda; Hiroyuki Hounoki; Reina Ogawa; Eiji Sugiyama; Kazuyuki Tobe

doi:10.1007/s00296-009-0931-6

Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment

Hirofumi Taki^*, Yukio Kawagishi, Koichiro Shinoda, Hiroyuki Hounoki, Reina Ogawa, Eiji Sugiyama, Kazuyuki Tobe

^*この論文の責任著者

内科学（第一）講座

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

32 被引用数 (Scopus)

抄録

Tumor necrosis factor (TNF)-α inhibitors are increasingly being used to treat rheumatoid arthritis. Infliximab (INF) is a TNF-α inhibitor that is usually used in combination with methotrexate (MTX). Interstitial lung disease (ILD) during combination therapy has been attributed to MTX rather than INF. However, INF-associated ILD without combination with MTX has recently been reported. We describe herein a case of severe ILD secondary to INF without MTX therapy.

本文言語	英語
ページ（範囲）	275-276
ページ数	2
ジャーナル	Rheumatology International
巻	30
号	2
DOI	https://doi.org/10.1007/s00296-009-0931-6
出版ステータス	出版済み - 2009/12

ASJC Scopus 主題領域

リウマチ学
免疫アレルギー学
免疫学

文献へのアクセス

10.1007/s00296-009-0931-6

引用スタイル

@article{8915e96c2c384af4906cb09c06d5ada3,

title = "Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment",

abstract = "Tumor necrosis factor (TNF)-α inhibitors are increasingly being used to treat rheumatoid arthritis. Infliximab (INF) is a TNF-α inhibitor that is usually used in combination with methotrexate (MTX). Interstitial lung disease (ILD) during combination therapy has been attributed to MTX rather than INF. However, INF-associated ILD without combination with MTX has recently been reported. We describe herein a case of severe ILD secondary to INF without MTX therapy.",

author = "Hirofumi Taki and Yukio Kawagishi and Koichiro Shinoda and Hiroyuki Hounoki and Reina Ogawa and Eiji Sugiyama and Kazuyuki Tobe",

year = "2009",

month = dec,

doi = "10.1007/s00296-009-0931-6",

language = "英語",

volume = "30",

pages = "275--276",

journal = "Rheumatology International",

issn = "0172-8172",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "2",

}

TY - JOUR

T1 - Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment

AU - Taki, Hirofumi

AU - Kawagishi, Yukio

AU - Shinoda, Koichiro

AU - Hounoki, Hiroyuki

AU - Ogawa, Reina

AU - Sugiyama, Eiji

AU - Tobe, Kazuyuki

PY - 2009/12

Y1 - 2009/12

N2 - Tumor necrosis factor (TNF)-α inhibitors are increasingly being used to treat rheumatoid arthritis. Infliximab (INF) is a TNF-α inhibitor that is usually used in combination with methotrexate (MTX). Interstitial lung disease (ILD) during combination therapy has been attributed to MTX rather than INF. However, INF-associated ILD without combination with MTX has recently been reported. We describe herein a case of severe ILD secondary to INF without MTX therapy.

AB - Tumor necrosis factor (TNF)-α inhibitors are increasingly being used to treat rheumatoid arthritis. Infliximab (INF) is a TNF-α inhibitor that is usually used in combination with methotrexate (MTX). Interstitial lung disease (ILD) during combination therapy has been attributed to MTX rather than INF. However, INF-associated ILD without combination with MTX has recently been reported. We describe herein a case of severe ILD secondary to INF without MTX therapy.

UR - http://www.scopus.com/inward/record.url?scp=71349084643&partnerID=8YFLogxK

U2 - 10.1007/s00296-009-0931-6

DO - 10.1007/s00296-009-0931-6

M3 - 学術論文

C2 - 19373466

AN - SCOPUS:71349084643

SN - 0172-8172

VL - 30

SP - 275

EP - 276

JO - Rheumatology International

JF - Rheumatology International

IS - 2

ER -

Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment

抄録

ASJC Scopus 主題領域

文献へのアクセス

フィンガープリント

引用スタイル